Maki Kiso1, Seiya Yamayoshi1, Jurika Murakami1, Yoshihiro Kawaoka1,2,3. 1. Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. 2. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA. 3. Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Abstract
BACKGROUND: Immunocompromised patients infected with influenza virus require prolonged treatment with neuraminidase inhibitors, because these patients are not able to eradicate the virus from the respiratory tract, leading to the emergence of drug-resistant mutant viruses. METHODS: In this study, we examined the efficacy of baloxavir marboxil in nude mice that were immunologically deficient. RESULTS: Daily treatment with a suboptimal dose of baloxavir marboxil increased the survival time of the virus-infected nude mice but did not clear the virus from their respiratory organs, resulting in gradual body weight loss after termination of treatment. CONCLUSIONS: Despite the prolonged baloxavir marboxil treatment, few resistant mutants were detected.
BACKGROUND: Immunocompromised patients infected with influenza virus require prolonged treatment with neuraminidase inhibitors, because these patients are not able to eradicate the virus from the respiratory tract, leading to the emergence of drug-resistant mutant viruses. METHODS: In this study, we examined the efficacy of baloxavir marboxil in nude mice that were immunologically deficient. RESULTS: Daily treatment with a suboptimal dose of baloxavir marboxil increased the survival time of the virus-infected nude mice but did not clear the virus from their respiratory organs, resulting in gradual body weight loss after termination of treatment. CONCLUSIONS: Despite the prolonged baloxavir marboxil treatment, few resistant mutants were detected.
Authors: Michael G Ison; Vasiliy P Mishin; Thomas J Braciale; Frederick G Hayden; Larisa V Gubareva Journal: J Infect Dis Date: 2006-02-13 Impact factor: 5.226
Authors: Christian Renaud; Alexandre A Boudreault; Jane Kuypers; Kathryn H Lofy; Lawrence Corey; Michael J Boeckh; Janet A Englund Journal: Emerg Infect Dis Date: 2011-04 Impact factor: 6.883
Authors: C Joaquin Caceres; Brittany Seibert; Flavio Cargnin Faccin; Stivalis Cardenas-Garcia; Daniela S Rajao; Daniel R Perez Journal: FEBS Open Bio Date: 2022-04-27 Impact factor: 2.792
Authors: Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin Journal: Antiviral Res Date: 2021-08-04 Impact factor: 10.103